Life Sciences Advisors

David P. Holveck — Endo Pharmaceuticals

David P. Holveck is President, Chief Executive Officer and a Director of Endo Pharmaceuticals.

Prior to joining Endo in April 2008, David was President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson & Johnson, a diversified healthcare company, since 2004. David joined Johnson & Johnson as a Company Group Chairman in 1999, following the acquisition of Centocor, Inc., a biotechnology company, by Johnson & Johnson.

David was Chief Executive Officer of Centocor, Inc. at the time of the acquisition. David joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. Prior to joining Centocor, he had held positions at General Electric Company, Corning Glass Works and Abbott Laboratories.

David is a member of the Board of Trustees for The Fund for West Chester University, as well as the Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA), the University City Science Center, and the Kimmel Center. David's knowledge of the Company, its operations and the evolving healthcare environment is valuable to the Board of Directors in evaluating and directing the Company’s future. Through his service on the boards of directors of other organizations as well as his prior senior executive positions at global pharmaceutical and healthcare product companies, David has developed extensive knowledge of operational leadership, risk oversight and management, as well as the pharmaceutical and device industries.